First Light Asset Management buys $14,353,211 stake in AtriCure (ATRC)

AtriCure (ATRC) : First Light Asset Management scooped up 4,653 additional shares in AtriCure during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 927,210 shares of AtriCure which is valued at $14,353,211.AtriCure makes up approximately 6.30% of First Light Asset Management’s portfolio.

Other Hedge Funds, Including , Tamarack Advisers Lp reduced its stake in ATRC by selling 189,000 shares or 36.0% in the most recent quarter. The Hedge Fund company now holds 336,000 shares of ATRC which is valued at $5,201,280. AtriCure makes up approx 1.77% of Tamarack Advisers Lp’s portfolio.Nuveen Asset Management boosted its stake in ATRC in the latest quarter, The investment management firm added 127,102 additional shares and now holds a total of 198,067 shares of AtriCure which is valued at $3,066,077. AtriCure makes up approx 0.02% of Nuveen Asset Management’s portfolio.Blackrock Japan Ltd reduced its stake in ATRC by selling 384 shares or 37.76% in the most recent quarter. The Hedge Fund company now holds 633 shares of ATRC which is valued at $9,799.California Public Employees Retirement System reduced its stake in ATRC by selling 1,300 shares or 3.06% in the most recent quarter. The Hedge Fund company now holds 41,200 shares of ATRC which is valued at $624,592.

AtriCure opened for trading at $15.45 and hit $15.58 on the upside on Thursday, eventually ending the session at $15.5, with a gain of 0.71% or 0.11 points. The heightened volatility saw the trading volume jump to 1,97,002 shares. Company has a market cap of $515 M.

On the company’s financial health, AtriCure reported $-0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.30. The company had revenue of $39.70 million for the quarter, compared to analysts expectations of $39.84 million. The company’s revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.

Many Wall Street Analysts have commented on AtriCure. AtriCure was Resumed by JMP Securities to “Mkt Outperform” on Jun 30, 2016.

AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.

Leave a Reply

AtriCure - Is it time to Sell?

Top Brokerage Firms are advising their investors on AtriCure. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.